MannKind Corp. (MNKD)

[TREND1]

morning star The warnings have been there.
You just had to read them.

Bears Say

Despite Afrezza's approval and partnership
with Sanofi, the product could flop on the market.
Exubera was removed from the market after it was
deemed a commercial failure thanks to its hefty
price tag and bulky design.

Beyond Afrezza, MannKind has only a few
early-stage products in its pipeline, making the
company's future almost entirely dependent on
Afrezza.

Safety concerns linking Exubera use to lung
cancer in former smokers prompted diabetes
experts such as Novo Nordisk and Eli Lilly to
discontinue their inhaled insulin products.